Cargando…

Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort

Background: Chemoradiotherapy (CRT) is a treatment standard in limited disease (LD) small cell lung cancer (SCLC). Currently, the timing of thoracic radiation therapy (TRT) remains the subject of randomised trials and meta-analyses. To investigate a correlation between CRT schedule parameters and ov...

Descripción completa

Detalles Bibliográficos
Autores principales: Manapov, Farkhad, Eze, Chukwuka, Niyazi, Maximilian, Roengvoraphoj, Olarn, Li, Minglun, Hegemann, Nina-Sophie, Hildebrandt, Guido, Fietkau, Rainer, Belka, Claus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118664/
https://www.ncbi.nlm.nih.gov/pubmed/27877216
http://dx.doi.org/10.7150/jca.16741
_version_ 1782468967669956608
author Manapov, Farkhad
Eze, Chukwuka
Niyazi, Maximilian
Roengvoraphoj, Olarn
Li, Minglun
Hegemann, Nina-Sophie
Hildebrandt, Guido
Fietkau, Rainer
Belka, Claus
author_facet Manapov, Farkhad
Eze, Chukwuka
Niyazi, Maximilian
Roengvoraphoj, Olarn
Li, Minglun
Hegemann, Nina-Sophie
Hildebrandt, Guido
Fietkau, Rainer
Belka, Claus
author_sort Manapov, Farkhad
collection PubMed
description Background: Chemoradiotherapy (CRT) is a treatment standard in limited disease (LD) small cell lung cancer (SCLC). Currently, the timing of thoracic radiation therapy (TRT) remains the subject of randomised trials and meta-analyses. To investigate a correlation between CRT schedule parameters and overall survival (OS) in a real-life patient cohort, a temporal analysis was performed. Methods: 182 LD SCLC patients successfully treated with definitive CRT were retrospectively reviewed. TRT was applied concurrently or sequentially. Impact of the treatment mode and interval of simultaneous treatment (IST) (an interval in days when chemotherapy and TRT were applied simultaneously, including time between chemotherapy cycles and weekends) on OS was analysed. Results: 71 (39%) patients were treated with concurrent and 111 (61%) with sequential CRT. Median overall survival (MS) for the entire cohort was 534 days (95%CI 461 - 607) without any significant difference between the concurrent and sequential groups (589: 95%CI 358 - 820 vs. 533: 95%CI 446 - 620 days, p=0.746, log-rank test). IST was 0 days in 111 (61%) patients treated sequentially whereas in the concurrent group, 20 (11%) and 51 (28%) patients showed an IST < 35 and > 35 days, respectively. Patients with IST > 0 and < 35 days demonstrated a trend to improved overall survival (MS: IST 0 vs. > 35 vs. < 35 was 533 vs. 448 vs. 1169 days, p=0.109, log-rank test). When patients treated with sequential CRT (IST 0) were excluded from the analysis, statistical difference in overall survival according to the IST subgroups (IST > 35 vs. < 35) became significant (p=0.021, log-rank test). On multivariate analysis of patients treated with concurrent CRT, IST > 0 and < 35 days remained a variable that significantly correlated with better overall survival (p=0.039, HR 0.38). Conclusion: In this real-life LD SCLC patient cohort, improved overall survival was achieved in patients treated with CRT schedule according to the IST > 0 and < 35-day concept. By exceeding the 35-day interval, we have seen deterioration in survival.
format Online
Article
Text
id pubmed-5118664
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-51186642016-11-22 Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort Manapov, Farkhad Eze, Chukwuka Niyazi, Maximilian Roengvoraphoj, Olarn Li, Minglun Hegemann, Nina-Sophie Hildebrandt, Guido Fietkau, Rainer Belka, Claus J Cancer Research Paper Background: Chemoradiotherapy (CRT) is a treatment standard in limited disease (LD) small cell lung cancer (SCLC). Currently, the timing of thoracic radiation therapy (TRT) remains the subject of randomised trials and meta-analyses. To investigate a correlation between CRT schedule parameters and overall survival (OS) in a real-life patient cohort, a temporal analysis was performed. Methods: 182 LD SCLC patients successfully treated with definitive CRT were retrospectively reviewed. TRT was applied concurrently or sequentially. Impact of the treatment mode and interval of simultaneous treatment (IST) (an interval in days when chemotherapy and TRT were applied simultaneously, including time between chemotherapy cycles and weekends) on OS was analysed. Results: 71 (39%) patients were treated with concurrent and 111 (61%) with sequential CRT. Median overall survival (MS) for the entire cohort was 534 days (95%CI 461 - 607) without any significant difference between the concurrent and sequential groups (589: 95%CI 358 - 820 vs. 533: 95%CI 446 - 620 days, p=0.746, log-rank test). IST was 0 days in 111 (61%) patients treated sequentially whereas in the concurrent group, 20 (11%) and 51 (28%) patients showed an IST < 35 and > 35 days, respectively. Patients with IST > 0 and < 35 days demonstrated a trend to improved overall survival (MS: IST 0 vs. > 35 vs. < 35 was 533 vs. 448 vs. 1169 days, p=0.109, log-rank test). When patients treated with sequential CRT (IST 0) were excluded from the analysis, statistical difference in overall survival according to the IST subgroups (IST > 35 vs. < 35) became significant (p=0.021, log-rank test). On multivariate analysis of patients treated with concurrent CRT, IST > 0 and < 35 days remained a variable that significantly correlated with better overall survival (p=0.039, HR 0.38). Conclusion: In this real-life LD SCLC patient cohort, improved overall survival was achieved in patients treated with CRT schedule according to the IST > 0 and < 35-day concept. By exceeding the 35-day interval, we have seen deterioration in survival. Ivyspring International Publisher 2016-10-17 /pmc/articles/PMC5118664/ /pubmed/27877216 http://dx.doi.org/10.7150/jca.16741 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.
spellingShingle Research Paper
Manapov, Farkhad
Eze, Chukwuka
Niyazi, Maximilian
Roengvoraphoj, Olarn
Li, Minglun
Hegemann, Nina-Sophie
Hildebrandt, Guido
Fietkau, Rainer
Belka, Claus
Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort
title Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort
title_full Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort
title_fullStr Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort
title_full_unstemmed Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort
title_short Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort
title_sort investigating a correlation between chemoradiotherapy schedule parameters and overall survival in a real-life ld sclc patient cohort
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118664/
https://www.ncbi.nlm.nih.gov/pubmed/27877216
http://dx.doi.org/10.7150/jca.16741
work_keys_str_mv AT manapovfarkhad investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort
AT ezechukwuka investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort
AT niyazimaximilian investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort
AT roengvoraphojolarn investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort
AT liminglun investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort
AT hegemannninasophie investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort
AT hildebrandtguido investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort
AT fietkaurainer investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort
AT belkaclaus investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort